pharma.markets

pharma.markets

  • HOME
  • Imprint

novartis

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

06/06/2022 MaP 0

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

12/12/2021 MaP 0

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of […]

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

12/12/2021 MaP 0

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation […]

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

09/12/2021 MaP 0

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall […]

Roche completed the repurchase of Roche shares from Novartis

06/12/2021 MaP 0

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November […]

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

19/11/2020 MaP 0

• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

26/06/2020 MaP 0

• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first […]

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

26/06/2020 MaP 0

• EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis • CHMP opinion based on two Phase […]

Novartis Resolves Legacy FCPA Investigations

25/06/2020 MaP 0

Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act […]

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

20/06/2020 MaP 0

• FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of […]

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

07/06/2020 MaP 0

• Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to […]

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149)

06/06/2020 MaP 0

….versus a free combination of two existing inhaled treatments in uncontrolled asthma • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a […]

Novartis provides update on FDA review of ofatumumab

03/06/2020 MaP 0

… a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis today announced that it has received notice from the US Food and […]

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

31/05/2020 MaP 0

• Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation […]

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

31/05/2020 MaP 0

• More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 • Study […]

Posts navigation

1 2 »

Translation

en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianja Japaneseko Koreanpt Portugueseru Russianes Spanish

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®
  • Pfizer and BioNTech Submit a Variation to EMA
  • Statement on Patent Infringement Lawsuit in Germany
  • Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
  • WHO highlights urgent need to transform mental health and mental health care

Archive

  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®

    08/07/2022 0
  • Pfizer and BioNTech Submit a Variation to EMA

    08/07/2022 0
  • Statement on Patent Infringement Lawsuit in Germany

    05/07/2022 0
  • Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

    17/06/2022 0
  • WHO highlights urgent need to transform mental health and mental health care

    17/06/2022 0
Archives
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid biontech cancer commission companies coronavirus covid-19 covid19 data economy elpais.com emergency eu europe european fda food global guarantee health hygiene links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support us vaccine vaccines who

Copyright © 2022 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner